Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blood (2024) 144 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2024-211012

Published: 2024

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

David Jung, Holly Lee, Sejal Chikhale, Mansour Poorebrahim, Sungwoo Ahn, Sacha Benaoudia, Noemie Leblay, Francesco Maura, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 591.

https://doi.org/10.1182/blood-2024-206347

Published: 2024

Journal Articles

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Tomas Jelinek, Serafim Nenarokov, Tereza Sevcikova, Eva Radova, Ondrej Venglar, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Ludmila Muronova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Bachisio Ziccheddu, Benjamin Diamond, Francesco Maura, Ola Landgren, David Zihala, Roman Hájek

Blood (2024) 144 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2024-206825

Published: 2024

Journal Articles

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Andrew Kowalski, David G. Coffey, Benjamin Diamond, James E. Hoffman, Marcella Kaddoura, Jill Lykon, Francesco Maura, Yahirini Rodriguez-Martinez, Suzan Rosen, Faika Shah, Dennis Verducci, Ola Landgren, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2024-203763

Published: 2024

Journal Articles

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Blood (2024) 144 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2024-200927

Published: 2024

Journal Articles

Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Hsuan-Ting Huang, Abdessamad Youssfi Alaoui, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz

Blood (2024) 144 (Supplement 1): 829.

https://doi.org/10.1182/blood-2024-203545

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

Blood (2024) 144 (Supplement 1): 248.

https://doi.org/10.1182/blood-2024-204341

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura

Blood (2024) 144 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2024-212294

Published: 2024

Journal Articles

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence H. Boise, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2024-211979

Published: 2024

Journal Articles

The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Olivia Barbara Lightfuss, Preet Kumar, Austin Daniel Newsam, Lingxiao Li, Pierre A. Younes, Toral Shastri, Abdessamad Youssfi Alaoui, Diego E. Hernandez Parets, Paola Manara, Daniel Bilbao, Stephan Schürer, Vance P. Lemmon, Francesco Maura, Yangbo Feng, Hassan A. Ali, Jonathan H. Schatz

Blood (2024) 144 (Supplement 1): 2781.

https://doi.org/10.1182/blood-2024-206073

Published: 2024

Journal Articles

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Afsaneh Panahi, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Dario Magaletti, Mark B. Meads, Kylee H Maclachlan, Marc S. Raab, Gareth Morgan, Saad Z. Usmani, Niels Weinhold, Ola Landgren, Kenneth H. Shain, Florian Kuchenbauer, Francesco Maura

Blood (2024) 144 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2024-211173

Published: 2024

Journal Articles

Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

Paola Manara, Venu Venkatarame Gowda Saralamma, Austin Daniel Newsam, Marco Vincenzo Russo, Tyler Andrew Cunningham, Alicia Bilbao Martinez, Nikolai Fattakhov, Kyle Hoffman, Alexandra Marie Carbone, Abdessamad Youssfi Alaoui, Dhanvantri Chahar, Olivia Barbara Lightfuss, Francesco Maura, Daniel Bilbao, Jonathan H. Schatz

Blood (2024) 144 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2024-203442

Published: 2024

Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2024-211833

Published: 2024

Journal Articles

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2024-205385

Published: 2024

Journal Articles

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David G. Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2024) 144 (Supplement 1): 932.

https://doi.org/10.1182/blood-2024-203426

Published: 2024

Journal Articles

Using Synthetic Data Produced By Artificial Intelligence (AI) to Generate Insights for Chimeric Antigen Receptor T-Cell (CAR T-Cell) Clinical Trials

Penelope Lafeuille, Afrah Shafquat, Chao Sang, Mandis Beigi, Francesco Maura, Jacob Aptekar

Blood (2024) 144 (Supplement 1): 7484.

https://doi.org/10.1182/blood-2024-203356

Published: 2024

NARROW

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Using Synthetic Data Produced By Artificial Intelligence (AI) to Generate Insights for Chimeric Antigen Receptor T-Cell (CAR T-Cell) Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only